Please confirm you are human (Sign Up for free to never see this)
← Back to Search
New Immunotherapeutic Drugs In Advanced Non-small Cell Lung Cancer (NSCLC): From Preclinical To Phase I Clinical Trials
Danilo Rocco, V. Gregorc, Luigi Della Gravara, C. Lazzari, G. Palazzolo, C. Gridelli
Published 2020 · Medicine
Save to my Library
Download PDFAnalyze on Scholarcy
ABSTRACT Introduction The development of immune checkpoint inhibitors (ICI) has represented a revolution in the treatment of non-small cell lung cancer (NSCLC) and has established a new standard of care for different settings. However, through adaptive changes, cancer cells can develop resistance mechanisms to these drugs, hence the necessity for novel immunotherapeutic agents. Areas covered This paper explores the immunotherapeutics currently under investigation in phase I clinical trials for the treatment of NSCLC as monotherapies and combination therapies. It provides two comprehensive tables of phase I agents which are listed according to target, drug, drug class, mechanism of action, setting, trial identifier, and trial status. A comprehensive literature search was carried out to identify eligible studies from MEDLINE/PubMed and ClinicalTrials.gov. Expert opinion A key hurdle to success in this field is our limited understanding of the synergic interactions of the immune targets in the context of the TME. While we can recognize the links between inhibitors and some particularly promising new targets such as TIM-3 and LAG3, we continue to develop approaches to exploit their interactions to enhance the immune response of the patient to tumor cells.
This paper references
TIM-3 plays a more important role than PD-1 in the functional impairments of cytotoxic T cells of malignant Schwannomas
Z. Li (2017)
Immune checkpoint inhibitors in malignant pleural mesothelioma.
G. Ceresoli (2017)
Drug resistance by evasion of antiangiogenic targeting of VEGF signaling in late-stage pancreatic islet tumors.
O. Casanovas (2005)
Present and future of cancer immunotherapy: A tumor microenvironmental perspective.
Yu Yu (2018)
VISTA Regulates the Development of Protective Antitumor Immunity.
I. Le Mercier (2014)
CD4/major histocompatibility complex class II interaction analyzed with CD4‐ and lymphocyte activation gene‐3 (LAG‐3)‐Ig fusion proteins
B. Huard (1995)
Cooperative Role of Interferon Regulatory Factor 1 and p91 (STAT1) Response Elements in Interferon-γ-inducible Expression of Human Indoleamine 2,3-Dioxygenase Gene*
S. Y. Chon (1996)
Molecular Pathways: The Immunogenic Effects of Platinum-Based Chemotherapeutics
Stanleyson V. Hato (2014)
Cutting Edge: OX40 Agonists Can Drive Regulatory T Cell Expansion if the Cytokine Milieu Is Right
C. Ruby (2009)
VISTA, a novel mouse Ig superfamily ligand that negatively regulates T cell responses
L. Wang (2011)
Tim-3 is an inducible human natural killer cell receptor that enhances interferon gamma production in response to galectin-9.
M. Gleason (2012)
T‐cell intrinsic effects of GITR and 4‐1BB during viral infection and cancer immunotherapy
L. Snell (2011)
Adaptive resistance to therapeutic PD-1 blockade is associated with upregulation of alternative immune checkpoints
S. Koyama (2016)
Phenotypic analysis of the murine CD4‐related glycoprotein, CD223 (LAG‐3)
C. Workman (2002)
Prevalence and Cellular Distribution of Novel Immune Checkpoint Targets Across Longitudinal Specimens in Treatment-naïve Melanoma Patients: Implications for Clinical Trials
J. Edwards (2019)
TIM‐3 is expressed on activated human CD4+ T cells and regulates Th1 and Th17 cytokines
W. Hastings (2009)
Immuno-Oncology: Emerging Targets and Combination Therapies
Henry T. Marshall (2018)
Lag-3, Tim-3, and TIGIT: Co-inhibitory Receptors with Specialized Functions in Immune Regulation.
A. Anderson (2016)
Next generation immune-checkpoints for cancer therapy.
Chiara Donini (2018)
Functional expression of CD134 by neutrophils
R. Baumann (2004)
LSECtin expressed on melanoma cells promotes tumor progression by inhibiting antitumor T-cell responses.
F. Xu (2014)
The immunoreceptor TIGIT regulates antitumor and antiviral CD8(+) T cell effector function.
Robert J. Johnston (2014)
Recognition of nectin-2 by the natural killer cell receptor T cell immunoglobulin and ITIM domain (TIGIT)
F. Deuss (2017)
IDO1 is an Integral Mediator of Inflammatory Neovascularization
Arpita Mondal (2016)
Indoleamine 2,3-Dioxygenase (IDO) Inhibition as a Strategy to Augment Cancer Immunotherapy
S. Yentz (2018)
Epacadostat plus pembrolizumab in patients with advanced melanoma and select solid tumors: Updated phase 1 results from ECHO-202/KEYNOTE-037
Tara C. Gangadhar (2016)
T follicular helper cell differentiation, function, and roles in disease.
S. Crotty (2014)
Biological Activity of Soluble CD100. I. The Extracellular Region of CD100 Is Released from the Surface of T Lymphocytes by Regulated Proteolysis1
A. Elhabazi (2001)
Lymphocyte activation gene‐3 induces tumor regression and antitumor immune responses
P. Prigent (1999)
OX40 promotes Bcl-xL and Bcl-2 expression and is essential for long-term survival of CD4 T cells.
P. Rogers (2001)
Cell-specific and context-dependent effects of GITR in cancer, autoimmunity, and infection.
Derek L. Clouthier (2014)
Adenosine A1 and A2A Receptors in the Brain: Current Research and Their Role in Neurodegeneration
Jocelyn Stockwell (2017)
TIM3+FOXP3+ regulatory T cells are tissue-specific promoters of T-cell dysfunction in cancer
Kaori Sakuishi (2013)
Clinical blockade of PD1 and LAG3 — potential mechanisms of action
L. T. Nguyen (2014)
The New Immunotherapy Combinations in the Treatment of Advanced Non-Small Cell Lung Cancer: Reality and Perspectives
Danilo Rocco (2019)
Selective inhibition of IDO1 effectively regulates mediators of antitumor immunity.
X. Liu (2010)
Enhanced suppressor function of TIM‐3+FoxP3+ regulatory T cells
A. Gautron (2014)
Overall Survival and Long-Term Safety of Nivolumab (Anti-Programmed Death 1 Antibody, BMS-936558, ONO-4538) in Patients With Previously Treated Advanced Non-Small-Cell Lung Cancer.
S. Gettinger (2015)
VISTA is an immune checkpoint molecule for human T cells.
J. L. Lines (2014)
Indoleamine-2,3-Dioxygenase in Non–Small Cell Lung Cancer: A Targetable Mechanism of Immune Resistance Frequently Coexpressed With PD-L1
Ashley Volaric (2018)
The use of polyethylene glycol‐modified interleukin‐2 (PEG‐IL‐2) in the treatment of patients with metastatic renal cell carcinoma and melanoma
J. Yang (1995)
Prognostic impact of CD73 and A2A adenosine receptor expression in non-small-cell lung cancer
Y. Inoue (2017)
Pivotal Roles of CD4+ Effector T cells in Mediating Agonistic Anti-GITR mAb-Induced-Immune Activation and Tumor Immunity in CT26 Tumors
Pengfei Zhou (2007)
Timing of PD-1 Blockade Is Critical to Effective Combination Immunotherapy with Anti-OX40
David J. Messenheimer (2017)
Modeling the receptor pharmacology, pharmacokinetics, and pharmacodynamics of NKTR-214, a kinetically-controlled interleukin-2 (IL2) receptor agonist for cancer immunotherapy
D. Charych (2017)
Extensive Profiling of the Expression of the Indoleamine 2,3-Dioxygenase 1 Protein in Normal and Tumoral Human Tissues
I. Théate (2014)
Treatment of advanced tumors with agonistic anti-GITR mAb and its effects on tumor-infiltrating Foxp3+CD25+CD4+ regulatory T cells
K. Ko (2005)
Indoleamine 2,3-Dioxygenase Expression in Human Cancers: Clinical and Immunologic Perspectives
Jessica Godin-Ethier (2011)
The promising immune checkpoint LAG-3: from tumor microenvironment to cancer immunotherapy
L. Long (2018)
The rationale of indoleamine 2,3-dioxygenase inhibition for cancer therapy.
L. Brochez (2017)
Lymphocyte‐activation gene 3/major histocompatibility complex class II interaction modulates the antigenic response of CD4+ T lymphocytes
B. Huard (1994)
CD100 Enhances Dendritic Cell and CD4+ Cell Activation Leading to Pathogenetic Humoral Responses and Immune Complex Glomerulonephritis1
M. Li (2006)
Depletion of regulatory T cells by anti-GITR mAb as a novel mechanism for cancer immunotherapy
David Coe (2010)
Molecular characterization of murine and human OX40/OX40 ligand systems: identification of a human OX40 ligand as the HTLV‐1‐regulated protein gp34.
P. Baum (1994)
The Semaphorin 4D-Plexin-B1-RhoA signaling axis recruits pericytes and regulates vascular permeability through endothelial production of PDGF-B and ANGPTL4
H. Zhou (2013)
Concurrent PD-1 Blockade Negates the Effects of OX40 Agonist Antibody in Combination Immunotherapy through Inducing T-cell Apoptosis
R. Shrimali (2017)
Coexpression of Tim-3 and PD-1 identifies a CD8+ T-cell exhaustion phenotype in mice with disseminated acute myelogenous leukemia.
Qing Zhou (2011)
Pre-treatment with chemotherapy can enhance the antigenicity and immunogenicity of tumours by promoting adaptive immune responses
W. Liu (2010)
Treg cells expressing the coinhibitory molecule TIGIT selectively inhibit proinflammatory Th1 and Th17 cell responses.
Nicole Joller (2014)
Gemcitabine Selectively Eliminates Splenic Gr-1+/CD11b+ Myeloid Suppressor Cells in Tumor-Bearing Animals and Enhances Antitumor Immune Activity
E. Suzuki (2005)
Characterization of the major histocompatibility complex class II binding site on LAG-3 protein.
B. Huard (1997)
Combination of immunotherapy with chemotherapy and radiotherapy in lung cancer: is this the beginning of the end for cancer?
C. Lazzari (2018)
TGF-β attenuates tumour response to PD-L1 blockade by contributing to exclusion of T cells
S. Mariathasan (2018)
IDO in the Tumor Microenvironment: Inflammation, Counter-Regulation, and Tolerance.
D. Munn (2016)
VISTA Is a Novel Broad-Spectrum Negative Checkpoint Regulator for Cancer Immunotherapy
J. L. Lines (2014)
Lymphocyte Activation Gene-3 (CD223) Regulates the Size of the Expanding T Cell Population Following Antigen Activation In Vivo1
C. Workman (2004)
The TIGIT/CD226 Axis Regulates Human T Cell Function
E. Lozano (2012)
Inhibitory receptors as targets for cancer immunotherapy
Meghan E. Turnis (2015)
Increased CD112 Expression in Methylcholanthrene-Induced Tumors in CD155-Deficient Mice
Y. Nagumo (2014)
Characterization of the lymphocyte activation gene 3-encoded protein. A new ligand for human leukocyte antigen class II antigens
E. Baixeras (1992)
LAG‐3 Protein Expression in Non–Small Cell Lung Cancer and Its Relationship with PD‐1/PD‐L1 and Tumor‐Infiltrating Lymphocytes
Y. He (2017)
OX40 engagement and chemotherapy combination provides potent antitumor immunity with concomitant regulatory T cell apoptosis
Daniel Hirschhorn-Cymerman (2009)
Loss of PTEN Promotes Resistance to T Cell-Mediated Immunotherapy.
W. Peng (2016)
Tim-3 marks human natural killer cell maturation and suppresses cell-mediated cytotoxicity.
L. Ndhlovu (2012)
Combined PD-1 blockade and GITR triggering induce a potent antitumor immunity in murine cancer models and synergizes with chemotherapeutic drugs
L. Lu (2013)
Indoleamine 2,3-dioxygenase 1 inhibition targets anti-PD1-resistant lung tumors by blocking myeloid-derived suppressor cells.
Ai-lin Li (2018)
New emerging targets in cancer immunotherapy: the role of TIM3
A. Friedlaender (2019)
OX40 is a potent immune-stimulating target in late-stage cancer patients.
B. Curti (2013)
OX40 Agonists and Combination Immunotherapy: Putting the Pedal to the Metal
S. Linch (2015)
GCN2 kinase in T cells mediates proliferative arrest and anergy induction in response to indoleamine 2,3-dioxygenase.
David H. Munn (2005)
Nucleotide signalling during inflammation
M. Idzko (2014)
Frontline: GITR, a member of the TNF receptor superfamily, is costimulatory to mouse T lymphocyte subpopulations
S. Ronchetti (2004)
CD8 T Cell-Intrinsic GITR Is Required for T Cell Clonal Expansion and Mouse Survival following Severe Influenza Infection
L. Snell (2010)
First-in-Human Phase I Study of the Oral Inhibitor of Indoleamine 2,3-Dioxygenase-1 Epacadostat (INCB024360) in Patients with Advanced Solid Malignancies
G. Beatty (2017)
511 Updated results from a phase 1/2 study of epacadostat (INCB024360) in combination with ipilimumab in patients with metastatic melanoma
Geoffrey T. Gibney (2015)
IDO is a nodal pathogenic driver of lung cancer and metastasis development.
C. Smith (2012)
TIM-3 Expression Characterizes Regulatory T Cells in Tumor Tissues and Is Associated with Lung Cancer Progression
X. Gao (2012)
Chronic inflammation that facilitates tumor progression creates local immune suppression by inducing indoleamine 2,3 dioxygenase
A. J. Muller (2008)
Targeting indoleamine‐2,3‐dioxygenase in cancer: Scientific rationale and clinical evidence
B. Ricciuti (2019)
Abstract CT116: BMS-986205, an optimized indoleamine 2,3-dioxygenase 1 (IDO1) inhibitor, is well tolerated with potent pharmacodynamic (PD) activity, alone and in combination with nivolumab (nivo) in advanced cancers in a phase 1/2a trial
L. Siu (2017)
Myeloid-derived suppressor cells as regulators of the immune system
D. Gabrilovich (2009)
The tumor microenvironment in non-small-cell lung cancer.
E. Graves (2010)
Early Effector T Lymphocytes Coexpress Multiple Inhibitory Receptors in Primary Non-Small Cell Lung Cancer.
E. Tassi (2017)
Peripheral blood gene expression of B7 and CD28 family members associated with tumor progression and microscopic lymphovascular invasion in colon cancer patients
Hyunji Lee (2010)
Molecular Pathways: Targeting IDO1 and Other Tryptophan Dioxygenases for Cancer Immunotherapy
L. Zhai (2015)
Blockade of the checkpoint receptor TIGIT prevents NK cell exhaustion and elicits potent anti-tumor immunity
Q. Zhang (2018)
Costimulation via Glucocorticoid-Induced TNF Receptor in Both Conventional and CD25+ Regulatory CD4+ T Cells1
F. Kanamaru (2004)
Glucocorticoid-induced tumor necrosis factor receptor–related protein co-stimulation facilitates tumor regression by inducing IL-9–producing helper T cells
I. Kim (2015)
Hepatitis C viral infection is associated with activated cytolytic natural killer cells expressing high levels of T cell immunoglobulin- and mucin-domain-containing molecule-3.
L. Golden-Mason (2015)
TIGIT: a novel immunotherapy target moving from bench to bedside
Benjamin L Solomon (2018)
Coexpression patterns of IDO-1, PD-L1 and EGFR in non-small cell lung cancer.
Weili Wang (2019)
Immunological mechanisms of the antitumor effects of supplemental oxygenation
Stephen M. Hatfield (2015)
Th1-specific cell surface protein Tim-3 regulates macrophage activation and severity of an autoimmune disease
L. Monney (2002)
Spatially Resolved and Quantitative Analysis of VISTA/PD-1H as a Novel Immunotherapy Target in Human Non–Small Cell Lung Cancer
F. Villarroel‐Espíndola (2017)
Tumor antigen-specific CD8+ T cells are negatively regulated by PD-1 and Tim-3 in human gastric cancer.
Xu Lu (2017)
GITR agonist enhances vaccination responses in lung cancer
L. Zhu (2015)
Elevated frequencies of CD8 T cells expressing PD-1, CTLA-4 and Tim-3 within tumour from perineural squamous cell carcinoma patients
R. Linedale (2017)
Abstract CT117: Interim analysis of the Phase 2 clinical trial of the IDO pathway inhibitor indoximod in combination with pembrolizumab for patients with advanced melanoma
Y. Zakharia (2017)
Soluble T Cell Immunoglobulin Mucin Domain 3 Is Shed from CD8+ T Cells by the Sheddase ADAM10, Is Increased in Plasma during Untreated HIV Infection, and Correlates with HIV Disease Progression
K. Clayton (2015)
GITR: a modulator of immune response and inflammation.
G. Nocentini (2009)
Safety, Pharmacokinetics, and Pharmacodynamics of a Humanized Anti-Semaphorin 4D Antibody, in a First-In-Human Study of Patients with Advanced Solid Tumors
A. Patnaik (2015)
The aryl hydrocarbon receptor: a perspective on potential roles in the immune system
E. Stevens (2009)
TIGIT signaling restores suppressor function of Th1 Tregs.
Liliana E. Lucca (2019)
Negative immune checkpoint regulation by VISTA: a mechanism of acquired resistance to anti-PD-1 therapy in metastatic melanoma patients
H. Kakavand (2017)
Immunoregulatory functions of VISTA
Elizabeth Nowak (2017)
The IDO1 selective inhibitor epacadostat enhances dendritic cell immunogenicity and lytic ability of tumor antigen-specific T cells
C. Jochems (2016)
Aryl hydrocarbon receptor negatively regulates dendritic cell immunogenicity via a kynurenine-dependent mechanism
N. T. Nguyen (2010)
Suppression of Tregs by anti-glucocorticoid induced TNF receptor antibody enhances the antitumor immunity of interferon-α gene therapy for pancreatic cancer
K. Aida (2014)
Epacadostat plus pembrolizumab versus placebo plus pembrolizumab in patients with unresectable or metastatic melanoma (ECHO-301/KEYNOTE-252): a phase 3, randomised, double-blind study.
G. Long (2019)
Stimulation of CD25+CD4+ regulatory T cells through GITR breaks immunological self-tolerance
J. Shimizu (2002)
Immunoreceptor TIGIT inhibits the cytotoxicity of human cytokine-induced killer cells by interacting with CD155
Baofu Zhang (2016)
Agonist Anti-GITR Monoclonal Antibody Induces Melanoma Tumor Immunity in Mice by Altering Regulatory T Cell Stability and Intra-Tumor Accumulation
A. Cohen (2010)
Expression and clinical significance of Semaphorin4D in non-small cell lung cancer and its impact on malignant behaviors of A549 lung cancer cells
Sha-Sha Ruan (2014)
Bempegaldesleukin selectively depletes intratumoral Tregs and potentiates T cell-mediated cancer therapy
M. Sharma (2020)
Evidence for a tumoral immune resistance mechanism based on tryptophan degradation by indoleamine 2,3-dioxygenase
C. Uyttenhove (2003)
Immunity, inflammation and cancer: a leading role for adenosine
L. Antonioli (2013)
Involvement of CD100, a lymphocyte semaphorin, in the activation of the human immune system via CD72: implications for the regulation of immune and inflammatory responses.
I. Ishida (2003)
Can IDO activity predict primary resistance to anti-PD-1 treatment in NSCLC?
A. Botticelli (2018)
Triggering of OX40 (CD134) on CD4(+)CD25+ T cells blocks their inhibitory activity: a novel regulatory role for OX40 and its comparison with GITR.
B. Valzasina (2005)
Human CD100, a novel leukocyte semaphorin that promotes B-cell aggregation and differentiation.
K. T. Hall (1996)
T cell immunoglobulin and mucin-domain containing-3 in non-small cell lung cancer.
Keyi Jia (2019)
The role of combination chemo-immunotherapy in advanced non-small cell lung cancer
Danilo Rocco (2019)
Hydroxyamidine Inhibitors of Indoleamine-2,3-dioxygenase Potently Suppress Systemic Tryptophan Catabolism and the Growth of IDO-Expressing Tumors
H. Koblish (2010)
Melanoma-intrinsic β-catenin signalling prevents anti-tumour immunity
Stefani Spranger (2015)
Targeting Tim-3 and PD-1 pathways to reverse T cell exhaustion and restore anti-tumor immunity
Kaori Sakuishi (2010)
NK cell expression of Tim-3: First impressions matter.
E. So (2019)
NKTR-214, an Engineered Cytokine with Biased IL2 Receptor Binding, Increased Tumor Exposure, and Marked Efficacy in Mouse Tumor Models
D. Charych (2016)
Updates in the Clinical Development of Epacadostat and Other Indoleamine 2,3-Dioxygenase 1 Inhibitors (IDO1) for Human Cancers
T. Komiya (2018)
OX40 and OX40L protein expression of tumor infiltrating lymphocytes in non-small cell lung cancer and its role in clinical outcome and relationships with other immune biomarkers.
Y. He (2019)
Mouse CD4 binds MHC class II with extremely low affinity.
S. Weber (1993)
Reprogramming the Tumor Microenvironment to Improve Immunotherapy: Emerging Strategies and Combination Therapies.
Meenal Datta (2019)
The Interplay between MicroRNAs and Cellular Components of Tumour Microenvironment (TME) on Non-Small-Cell Lung Cancer (NSCLC) Progression
S. S. Lee (2019)
CD4(+)CD25(+) immunoregulatory T cells: gene expression analysis reveals a functional role for the glucocorticoid-induced TNF receptor.
R. McHugh (2002)